Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and ro (Q39153790)
Jump to navigation
Jump to search
scientific article published on 3 June 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and ro |
scientific article published on 3 June 2013 |
Statements
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity (English)
Steve Sideris
Timothy P Heffron
Jim Nonomiya
Alan G Olivero
Steven T Staben
Matthew Baumgardner
Nicole Blaquiere
Erin Bradley
Richard Bull
Steven Do
Jennafer Dotson
Danette Dudley
Kyle A Edgar
Lori S Friedman
Richard Goldsmith
Robert A Heald
Aleksandr Kolesnikov
Leslie Lee
Cristina Lewis
Michelle Nannini
Steve Price
Wei Wei Prior
Laurent Salphati
Jeffery J Wallin
Lan Wang
BinQing Wei